Last week was about follow-through. CMS finally acted on the EARLY TAVR data it has been sitting on since 2024. Stryker learned that a March cyberattack has a longer tail than it told investors in July. Intuitive answered two new competitors with 14 million cases of evidence. Zimmer Biomet rebuilt its org chart around a robot that doesn't ship until 2027. Announcements are cheap; this was a week of paying for them.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🏛️ CMS finalizes TAVR coverage for asymptomatic severe aortic stenosis
On Thursday CMS finalized the TAVR national coverage determination it has been reconsidering since Edwards’ request last year. Medicare now covers asymptomatic severe AS under a coverage-with-evidence-development requirement, and symptomatic severe AS loses its CED requirement entirely. Heart-team and on-site cardiac surgery requirements stay. This is the reimbursement half of a two-part expansion; the FDA label came earlier this year. Edwards and Medtronic get a larger addressable patient pool at the exact moment structural-heart growth was decelerating, and every hospital TAVR program now has a reason to revisit its referral funnel.
Cardiovascular Business
2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Sponsored by RŌG Health
3. 🛡️ Stryker’s cyberattack fallout stretches into Q4, stock hits 52-week low
CFO Preston Wells told the Wells Fargo conference that peripheral vascular supply disruptions from the March attack, which management said in July would be manageable by end of Q3, will now run into Q4, and that the constraint is blocking new business wins, not just fulfillment. Hip sales were soft too. Shares fell roughly 10% on the week and Wells Fargo cut its target by $70 while keeping the rating. Guidance held. Meanwhile Boston Scientific said it has fully restored manufacturing and shipping after its own August incident. The lesson from both: the market is now pricing cyber resilience as an operating metric, and “we’re back online” and “we’re back to full inventory” are separated by quarters, not days.
MedTech Dive
4. 🤖 Intuitive publishes a 14-million-case meta-analysis backing da Vinci in benign surgery
A systematic review in Annals of Surgery Open, led by a Mass General Brigham surgeon with Intuitive co-authors, pooled 366 studies across 32 countries and found robotic surgery associated with better select perioperative outcomes than laparoscopic and open approaches across 13 benign conditions. The timing is the story. Medtronic’s Hugo and J&J’s Ottava both cleared for U.S. soft tissue within the past year, and benign general surgery is precisely where bears expect share loss. Intuitive is choosing to compete on the evidence base rather than the hardware, which is the one asset a new entrant can’t buy.
Intuitive Surgical
5. 🦴 Zimmer Biomet splits its Americas leadership ahead of the Monogram robot
Zimmer promoted three executives into a new three-way structure (Americas commercial, global recon portfolio, and a standalone robotics/technology/data president) and parted with former Nevro CEO Kevin Thornal, who leaves Sept. 30 after roughly a year. The stated purpose is to build a dedicated robotics sales force before the 2027 Monogram launch, in parallel with the ongoing conversion of its 2,500-person U.S. sales force from contractors to employees. The same week, Zimmer proposed cutting 580 jobs at its Winterthur, Switzerland plant. Reorganizing the commercial org before the product exists is the right sequence; it’s also a lot of change to absorb at once.
MedTech Dive
6. ⌚ Apple Watch Ultra 4 ships a readiness score, not a blood pressure reading
Apple unveiled the Ultra 4 with a redesigned sensor system on its S11 chip: more frequent HRV sampling, a daily readiness score, a “Health Age” metric, and what Apple calls the most accurate heart-rate sensing in a wearable, per its own 1,000-participant study. The blood pressure feature that dominated pre-event reporting didn’t make it. Read alongside Oura’s S-1 last week, the picture is clear: the consumer wearable majors are converging on the same recovery-and-readiness lane and holding their regulated features in reserve until the FDA process finishes.
MassDevice
7. 🧠 Nvidia takes an equity stake in Verily
Verily extended its March $300M round with new money from Nvidia and a follow-on from CU Healthcare Innovation Fund; terms weren’t disclosed. The two companies already collaborate on Verily’s Pre data platform and the Forecast 1.0 foundation model that fuses genomics with EHR data. Nvidia converting a technology partnership into a shareholding is a pattern it’s repeating across healthcare AI, and it’s worth watching for anyone whose device roadmap assumes a neutral compute layer underneath.
R&D World
8. 🔬 Galleri goes to an FDA advisory panel Sept. 23; public docket closes Wednesday
A look-ahead: the Molecular and Clinical Genetics Panel meets a week from Wednesday to vote on GRAIL’s PMA for the Galleri multi-cancer early detection test, the first MCED to reach an FDA panel. The public comment docket (FDA-2026-N-8004) closes Sept. 16. The PMA rests on PATHFINDER 2 and the NHS-Galleri trial. The panel’s vote is non-binding, but the questions it asks about how a screening test with modest sensitivity fits into a population program will set the frame for every MCED that follows.
FDA
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.